British drug giant GSK is reportedly in talks to acquire cancer drugmaker Nuvalent. The deal could be worth over nine billion dollars. Disc...

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

Toregem BioPharma has secured $5.3 million to advance its experimental tooth-regeneration drug, TRG035, into Phase II clinical trials. The ...

India faces a challenging global economic outlook for 2026-27. Geopolitical tensions and volatile oil prices are key concerns. However, Ind...

Jammu and Kashmir has achieved a record investment of over ₹5,800 crore in 2025-26. This marks a significant jump, thirteen times higher th...

Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...

Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...

Biocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges im...

Biocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...

Guardant Health is set to introduce a groundbreaking blood test in India for early cancer detection. This multi-cancer test, co-marketed by...

The Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medici...

Moderna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

The proposed fund aims to position India as a global biopharma manufacturing hub

Hyderabad, Dec 9- Prestige BioPharma Ltd, a Singapore-based firm and Dr. Reddy's Laboratories Ltd., on Thursday announced that the two comp...

Ahead of the 14th edition of the annual BioPharma and Healthcare Summit, that bring stakeholders from India and the United States on one pl...

India's bio-pharma sector may see a surge in R&D spending to about $25 billion in the next 15 years, according to a Boston Consulting Group...